NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free DYN Stock Alerts $26.00 +0.05 (+0.19%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$25.07▼$26.4850-Day Range$23.65▼$29.1852-Week Range$6.40▼$30.27Volume538,840 shsAverage Volume780,539 shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice Target$37.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Dyne Therapeutics alerts: Email Address Dyne Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.13 Rating ScoreUpside/Downside45.2% Upside$37.75 Price TargetShort InterestBearish18.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 21 Articles This WeekInsider TradingSelling Shares$44.37 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.10) to ($3.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector293rd out of 921 stocksPharmaceutical Preparations Industry124th out of 428 stocks 4.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.91% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Dyne Therapeutics has recently increased by 6.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 2.6 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Dyne Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $44,368,530.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.10) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -6.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Dyne Therapeutics Stock (NASDAQ:DYN)Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesMay 10, 2024 | americanbankingnews.comDyne Therapeutics, Inc. to Post FY2024 Earnings of ($2.87) Per Share, Chardan Capital Forecasts (NASDAQ:DYN)May 9, 2024 | americanbankingnews.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:DYN)May 11, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.May 8, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Stock Rating Reaffirmed by OppenheimerMay 8, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Rating Reiterated by Chardan CapitalMay 7, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Dyne Therapeutics (NASDAQ:DYN)May 6, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)May 6, 2024 | markets.businessinsider.comRobust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne TherapeuticsMay 11, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.May 4, 2024 | finance.yahoo.comWe're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash WiselyMay 4, 2024 | finance.yahoo.comDyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst ProjectionsMay 3, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 3, 2024 | americanbankingnews.comFinancial Contrast: Dyne Therapeutics (NASDAQ:DYN) versus Leap Therapeutics (NASDAQ:LPTX)May 3, 2024 | msn.comDYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 2, 2024 | globenewswire.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 1, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Morgan StanleyApril 30, 2024 | msn.comMorgan Stanley Initiates Coverage of Dyne Therapeutics (DYN) with Overweight RecommendationApril 22, 2024 | finanznachrichten.deSynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCTApril 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)March 27, 2024 | globenewswire.comDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerMarch 27, 2024 | globenewswire.comDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumMarch 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Dyne Therapeutics (DYN), Addus Homecare (ADUS)March 25, 2024 | bizjournals.comDyne announces CEO transition, former Biogen exec tapped for top spotMarch 25, 2024 | marketwatch.comDyne Therapeutics Shares Drop 14% on CEO Joshua Brumm DepartureMarch 25, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO TransitionMarch 25, 2024 | markets.businessinsider.comDyne Therapeutics Appoints John Cox As CEO To Succeed Joshua BrummSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$37.75 High Stock Price Target$56.00 Low Stock Price Target$22.00 Potential Upside/Downside+45.2%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-110.92% Return on Assets-90.00% Debt Debt-to-Equity RatioN/A Current Ratio21.83 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.47 per share Price / Book4.75Miscellaneous Outstanding Shares87,380,000Free Float69,234,000Market Cap$2.27 billion OptionableOptionable Beta1.00 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Susanna Gatti High M.B.A. (Age 56)Chief Operating Officer Comp: $754.1kDr. Jonathan McNeill M.D. (Age 39)Chief Business Officer Comp: $662.34kMr. John G. Cox M.B.A. (Age 61)CEO, President & Director Dr. Romesh Subramanian Ph.D. (Age 59)Co-Founder & Advisor Comp: $565.17kMr. Richard William Scalzo M.B.A. (Age 38)Senior VP and Head of Finance & Administration Mr. John Najim M.B.A.Chief Technical OfficerDr. Oxana Beskrovnaya Ph.D. (Age 63)Chief Scientific Officer Comp: $631.08kMs. Amy Reilly (Age 50)Senior VP and Head of Corporate Communications & Investor Relations Mr. Daniel Wilson (Age 52)Senior VP & Head of Legal Ms. Kate MitchellVP & Head of Human ResourcesMore ExecutivesKey CompetitorsMaravai LifeSciencesNASDAQ:MRVIGeronNASDAQ:GERNArvinasNASDAQ:ARVNArdelyxNASDAQ:ARDXRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 1,110,629 shares on 5/10/2024Ownership: 3.937%Russell Investments Group Ltd.Bought 1,447 shares on 5/8/2024Ownership: 0.117%ProShare Advisors LLCBought 5,028 shares on 5/8/2024Ownership: 0.019%Sei Investments Co.Bought 24,410 shares on 5/7/2024Ownership: 0.028%Concurrent Investment Advisors LLCBought 20,200 shares on 5/7/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions DYN Stock Analysis - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last twelve months. There are currently 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price target for 2024? 8 brokers have issued 1 year price objectives for Dyne Therapeutics' shares. Their DYN share price targets range from $22.00 to $56.00. On average, they expect the company's share price to reach $37.75 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2024? Dyne Therapeutics' stock was trading at $13.30 at the beginning of the year. Since then, DYN stock has increased by 95.5% and is now trading at $26.00. View the best growth stocks for 2024 here. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) posted its earnings results on Tuesday, March, 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.17. What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NASDAQ:DYN) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares Micro-Cap ETF (IWC). When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an initial public offering (IPO) on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (9.18%), Vanguard Group Inc. (3.94%), Vivo Capital LLC (1.90%), Jennison Associates LLC (1.40%), Wasatch Advisors LP (0.48%) and Vida Ventures Advisors LLC (0.47%). Insiders that own company stock include Dirk Kersten, Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Oxana Beskrovnaya, Richard William Scalzo, Susanna Gatti High, Venture Fund Xi LP Atlas and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DYN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
